What Does IQVIA Holdings ($IQV) Do? – Stock Outlook, Earnings, Market Cap, Peers & Headquarters
IQVIA Holdings (IQV) is a global contract research organization and healthcare data analytics specialist, distinguished by its extensive global clinical infrastructure and stable revenue visibility. Summary of IQV stock, outlook, earnings, peers, and revenue.
🏢 What kind of company is IQVIA Holdings?
IQVIA Holdings (IQV) is a global integrated healthcare services company headquartered in Durham, North Carolina, USA. Its business model combines contract research organization (CRO) services with global prescription and medical-claims data analytics, delivering integrated clinical, commercialization, and analytics services to pharmaceutical, biotech, and medical-device clients.
It operates an integrated portfolio spanning global clinical research and clinical operations services, healthcare data and analytics technology solutions, and pharmaceutical commercialization and market access consulting. Broad global clinical infrastructure and proprietary prescription and medical-claims data assets form the core barriers to entry for the business.
How does IQVIA Holdings make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| Research & Development Solutions (R&DS) | Core | Clinical research outsourcing & clinical operations |
| Technology & Analytics Solutions (TAS) | Key growth driver | Healthcare data, technology & analytics |
| Contract Sales & Medical Solutions (CSMS) | Diversification driver | Pharmaceutical commercialization & market access |
| Other / Services | Supplementary | Other service revenue |
The Research & Development Solutions segment accounts for the largest share of revenue, while Technology & Analytics Solutions and Contract Sales & Medical Solutions form diversified revenue pillars. Global pharmaceutical and biotech R&D investment, clinical trial order intake, and growing demand for healthcare data utilization are the key drivers of revenue flow. Cumulative order backlog and broad global clinical infrastructure underpin revenue visibility.
📐 IQVIA Holdings Market Cap and Company Scale
Market capitalization stands at $41.3B, and the company employs 93,000명 people.
It is a top-tier integrated healthcare services company by market cap within the global contract research and healthcare data analytics group, evaluated alongside fellow clinical trial outsourcing peers ICLR, SYNH, and MEDP. The company maintains stable revenue visibility and an active capital return policy through buybacks, while its global clinical infrastructure and data assets serve as structural moats for business value.
📈 IQVIA Holdings Outlook and Stock Trends
Recovery in global pharmaceutical and biotech R&D investment, growing demand for healthcare data utilization, and AI-driven clinical operations efficiency are the medium- to long-term growth drivers. Expansion of clinical trials in global emerging markets and growth of the pharmaceutical commercialization consulting business are additional supporting growth pillars. In the short term, global biotech funding cycles, clinical trial order intake, and FX volatility are volatility factors, while order share competition with contract clinical research peers should also be monitored as a short-term variable.
- Global R&D investment recovery
- Healthcare data utilization demand
- AI-driven clinical efficiency
⚔️ IQVIA Holdings Key Strengths and Risks
Broad global clinical infrastructure and prescription and medical-claims data assets are strengths, while biotech funding cycle volatility and FX exposure are the key risks.
💪 Key Strengths
⚠️ Key Risks
🔄 IQVIA Holdings Competitors and Related Stocks (Beneficiaries)
Direct competitors in global clinical research include fellow contract clinical research peers ICLR, SYNH, and MEDP. Related names include life sciences tools mega-cap names TMO and DHR, along with global analytical instruments group A on the clinical infrastructure supply chain side, while global large-cap pharma and biotech names PFE, LLY, and MRK are monitored together on the client-business side.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
 ICLR | Icon Plc | $177.87 | -1.3% | $13.6B | 81.9 | 1.5 | 1.85% | - |
 MEDP | Medpace Holdings Inc | $584.93 | +2.4% | $16.3B | 34.3 | 37.5 | 162.15% | - |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc | $576.46 | +0.0% | $214.2B | 31.0 | 4.1 | 13.53% | 0.32% |
| DHR | Danaher Corp | $196.49 | -1.3% | $138.1B | 34.9 | 2.6 | 7.61% | 0.73% |
| A | Agilent Technologies Inc | $140.30 | -0.2% | $39.6B | 28.2 | 5.6 | 21.33% | 0.73% |
| PFE | Pfizer Inc | $25.15 | -0.4% | $143.3B | 19.3 | 1.6 | 8.29% | 6.85% |
| LLY | Lilly(Eli) & Co | $1210.02 | -0.9% | $1.14T | 43.6 | 36.6 | 107.64% | 0.58% |
| MRK | Merck & Co Inc | $130.36 | -1.1% | $322.0B | 36.7 | 7.0 | 18.97% | 2.51% |
✅ IQVIA Holdings Investor Checkpoints
Key checkpoints to review when investing in IQVIA Holdings include the global R&D investment cycle, clinical trial order intake, healthcare data utilization demand, and capital return flow.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🔬 R&D Cycle | Global pharma & biotech capex | Cycle recovery phase |
| 📋 Clinical Orders | Clinical trial order backlog trend | Expanding trend |
| 📊 Data Analytics | Healthcare data analytics revenue | Growing trend |
| 💰 Capital Return | Share buyback trend | Steady return flow |
Clinical trial order intake may slow during biotech funding pullback phases. Order share competition with contract clinical research peers, FX volatility, and a slowdown in the global pharma and biotech capex cycle are also factors that should be monitored together as short-term volatility drivers.
IQVIA Holdings is a global healthcare services core name combining broad global clinical infrastructure with prescription and medical-claims data assets. Given cyclical volatility, dollar-cost averaging and a long-term perspective are recommended.
이 글은 2026년 5월 21일 기준 정보입니다.